Do analysts prefer MCRB or AIMD?

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 221.60%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Seres Therapeutics is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MCRB or AIMD more profitable?

Seres Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Seres Therapeutics' return on equity of -130.29% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Ainos -11,912.10% -186.12% -66.07%

Do analysts recommend AIMD or CPHI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, AIMD or CPHI?

China Pharma has higher revenue and earnings than Ainos. China Pharma is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $120K 98.76 -$14.77M -$2.89 N/A China Pharma $3.99M 12.67 -$3.08M -$0.55 N/A

Is AIMD or CPHI more profitable?

China Pharma has a net margin of -85.56% compared to Ainos' net margin of -11,912.10%. China Pharma's return on equity of -63.93% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -186.12% -66.07% China Pharma -85.56% -63.93% -31.42%

Do analysts rate AIMD or MGX?

Metagenomi has a consensus price target of $7.00, indicating a potential upside of 476.13%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has preferable earnings and valuation, AIMD or MGX?

Ainos has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $120K 98.76 -$14.77M -$2.89 N/A Metagenomi $25.21M 1.81 -$87.87M -$2.30 N/A

Is AIMD or MGX more profitable?

Metagenomi has a net margin of -384.61% compared to Ainos' net margin of -11,912.10%. Metagenomi's return on equity of -51.23% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -186.12% -66.07% Metagenomi -384.61% -51.23% -36.62%

Do analysts recommend INMB or AIMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, INMB or AIMD?

Ainos has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,004.72 -$45.93M -$1.67 N/A Ainos $120K 98.76 -$14.77M -$2.89 N/A

Is INMB or AIMD more profitable?

INmune Bio has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. INmune Bio's return on equity of -103.03% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Ainos -11,912.10% -186.12% -66.07%

Do analysts prefer AIMD or TCRT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AIMD or TCRT more profitable?

Alaunos Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Alaunos Therapeutics' return on equity of -165.94% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -186.12% -66.07% Alaunos Therapeutics N/A -165.94% -123.50%

Ainos (AIMD) Competitors

$1.39 -0.02 (-1.35%)

As of 01:01 PM Eastern

Compare

AIMD vs. MCRB, CPHI, MGX, INMB, and TCRT

Should you buy Ainos stock or one of its competitors? MarketBeat compares Ainos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ainos include Seres Therapeutics (MCRB), China Pharma (CPHI), Metagenomi (MGX), INmune Bio (INMB), and Alaunos Therapeutics (TCRT).

How does Ainos compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Ainos (NASDAQ:AIMD) are related small-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Seres Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Ainos has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

Seres Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Seres Therapeutics' return on equity of -130.29% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Ainos	-11,912.10%	-186.12%	-66.07%

In the previous week, Seres Therapeutics had 3 more articles in the media than Ainos. MarketBeat recorded 4 mentions for Seres Therapeutics and 1 mentions for Ainos. Seres Therapeutics' average media sentiment score of 0.00 beat Ainos' score of -0.47 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Ainos	Neutral

59.3% of Seres Therapeutics shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Seres Therapeutics has higher revenue and earnings than Ainos. Seres Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$1.15M	44.63	$5.70M	-$5.17	N/A
Ainos	$120K	98.76	-$14.77M	-$2.89	N/A

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 221.60%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Seres Therapeutics is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Seres Therapeutics beats Ainos on 11 of the 16 factors compared between the two stocks.

How does Ainos compare to China Pharma?

Ainos (NASDAQ:AIMD) and China Pharma (NYSE:CPHI) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

China Pharma has a net margin of -85.56% compared to Ainos' net margin of -11,912.10%. China Pharma's return on equity of -63.93% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-186.12%	-66.07%
China Pharma	-85.56%	-63.93%	-31.42%

In the previous week, Ainos and Ainos both had 1 articles in the media. China Pharma's average media sentiment score of 0.00 beat Ainos' score of -0.47 indicating that China Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Ainos	Neutral
China Pharma	Neutral

China Pharma has higher revenue and earnings than Ainos. China Pharma is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	98.76	-$14.77M	-$2.89	N/A
China Pharma	$3.99M	12.67	-$3.08M	-$0.55	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ainos has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Summary

China Pharma beats Ainos on 7 of the 11 factors compared between the two stocks.

How does Ainos compare to Metagenomi?

Ainos (NASDAQ:AIMD) and Metagenomi (NASDAQ:MGX) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Ainos has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Ainos has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	98.76	-$14.77M	-$2.89	N/A
Metagenomi	$25.21M	1.81	-$87.87M	-$2.30	N/A

In the previous week, Ainos had 1 more articles in the media than Metagenomi. MarketBeat recorded 1 mentions for Ainos and 0 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.00 beat Ainos' score of -0.47 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Overall Sentiment
Ainos	Neutral
Metagenomi	Neutral

Metagenomi has a net margin of -384.61% compared to Ainos' net margin of -11,912.10%. Metagenomi's return on equity of -51.23% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-186.12%	-66.07%
Metagenomi	-384.61%	-51.23%	-36.62%

Metagenomi has a consensus price target of $7.00, indicating a potential upside of 476.13%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Metagenomi beats Ainos on 10 of the 15 factors compared between the two stocks.

How does Ainos compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Ainos (NASDAQ:AIMD) are related small-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

12.7% of INmune Bio shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 9.8% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

INmune Bio has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Ainos has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, INmune Bio had 3 more articles in the media than Ainos. MarketBeat recorded 4 mentions for INmune Bio and 1 mentions for Ainos. INmune Bio's average media sentiment score of 0.20 beat Ainos' score of -0.47 indicating that INmune Bio is being referred to more favorably in the media.

Company	Overall Sentiment
INmune Bio	Neutral
Ainos	Neutral

Ainos has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,004.72	-$45.93M	-$1.67	N/A
Ainos	$120K	98.76	-$14.77M	-$2.89	N/A

INmune Bio has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. INmune Bio's return on equity of -103.03% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Ainos	-11,912.10%	-186.12%	-66.07%

Summary

INmune Bio beats Ainos on 10 of the 15 factors compared between the two stocks.

How does Ainos compare to Alaunos Therapeutics?

Ainos (NASDAQ:AIMD) and Alaunos Therapeutics (NASDAQ:TCRT) are related small-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Ainos has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the broader market.

Alaunos Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Alaunos Therapeutics' return on equity of -165.94% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-186.12%	-66.07%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Alaunos Therapeutics has lower revenue, but higher earnings than Ainos. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	98.76	-$14.77M	-$2.89	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

27.7% of Alaunos Therapeutics shares are held by institutional investors. 9.8% of Ainos shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Ainos had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 1 mentions for Ainos and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 beat Ainos' score of -0.47 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ainos	Neutral
Alaunos Therapeutics	Neutral

Summary

Alaunos Therapeutics beats Ainos on 7 of the 12 factors compared between the two stocks.

Get Ainos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIMD vs. The Competition

Export

Metric	Ainos	Technology Hardware, Storage & Peripherals Industry	Technology Sector	NASDAQ Exchange
Market Cap	$11.86M	$107.50B	$29.79B	$12.94B
Dividend Yield	N/A	1.71%	2.76%	10.01%
P/E Ratio	-0.48	37.56	81.95	25.55
Price / Sales	98.76	124.69	598.63	91.90
Price / Cash	N/A	23.54	47.90	49.40
Price / Book	1.08	8.20	9.27	6.10
Net Income	-$14.77M	$3.10B	$662.76M	$348.05M
7 Day Performance	5.38%	9.94%	6.87%	4.87%
1 Month Performance	-25.61%	0.03%	-1.21%	-2.01%
1 Year Performance	-40.30%	98.47%	152.44%	21.16%

Ainos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIMD Ainos	0.4227 of 5 stars	$1.39 -1.3%	N/A	-42.9%	$11.86M	$120K	N/A	40	Earnings Report Gap Down
MCRB Seres Therapeutics	2.2622 of 5 stars	$4.84 +4.1%	$17.00 +251.2%	-64.5%	$46.87M	$1.15M	N/A	330	News Coverage Gap Up
CPHI China Pharma	N/A	$1.15 -4.6%	N/A	-26.3%	$46.40M	$3.99M	N/A	250
MGX Metagenomi	3.105 of 5 stars	$1.22 +0.8%	$7.00 +473.8%	-47.4%	$45.93M	$25.21M	N/A	236	Upcoming Earnings
INMB INmune Bio	1.0454 of 5 stars	$1.72 +1.7%	N/A	-33.2%	$45.59M	$50K	N/A	10	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIMD) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ainos (AIMD) Competitors

AIMD vs. MCRB, CPHI, MGX, INMB, and TCRT

How does Ainos compare to Seres Therapeutics?

Summary

How does Ainos compare to China Pharma?

Summary

How does Ainos compare to Metagenomi?

Summary

How does Ainos compare to INmune Bio?

Summary

How does Ainos compare to Alaunos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD vs. The Competition

Ainos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ainos (AIMD) Competitors

AIMD vs. MCRB, CPHI, MGX, INMB, and TCRT

How does Ainos compare to Seres Therapeutics?

Which has more volatility and risk, MCRB or AIMD?

Is MCRB or AIMD more profitable?

Does the media favor MCRB or AIMD?

Do institutionals & insiders hold more shares of MCRB or AIMD?

Which has higher valuation & earnings, MCRB or AIMD?

Do analysts prefer MCRB or AIMD?

Summary

How does Ainos compare to China Pharma?

Is AIMD or CPHI more profitable?

Does the media favor AIMD or CPHI?

Which has stronger earnings & valuation, AIMD or CPHI?

Do analysts recommend AIMD or CPHI?

Which has more volatility and risk, AIMD or CPHI?

Summary

How does Ainos compare to Metagenomi?

Which has more volatility & risk, AIMD or MGX?

Which has preferable earnings and valuation, AIMD or MGX?

Does the media prefer AIMD or MGX?

Is AIMD or MGX more profitable?

Do analysts rate AIMD or MGX?

Summary

How does Ainos compare to INmune Bio?

Do institutionals and insiders hold more shares of INMB or AIMD?

Which has more risk and volatility, INMB or AIMD?

Do analysts recommend INMB or AIMD?

Does the media favor INMB or AIMD?

Which has higher earnings & valuation, INMB or AIMD?

Is INMB or AIMD more profitable?

Summary

How does Ainos compare to Alaunos Therapeutics?

Which has more volatility and risk, AIMD or TCRT?

Is AIMD or TCRT more profitable?

Which has stronger valuation and earnings, AIMD or TCRT?

Do analysts prefer AIMD or TCRT?

Do insiders and institutionals believe in AIMD or TCRT?

Does the media refer more to AIMD or TCRT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD vs. The Competition

Ainos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools